| answer text |
<p>Following the reforms to the Cancer Drugs Fund (CDF) in July 2016 all new cancer
drugs and significant new licensed indications for existing drugs are referred to
the National Institute for Health and Care Excellence (NICE). This included the referral
of all licensed cancer drug indications for rare cancers that had not previously been
assessed by NICE.</p><p>This has led to an increase in the number, and proportion,
of NICE appraisals of treatments for rare cancers. Since July 2016 21% or 24 out of
114 cancer drugs appraised by NICE have been for rarer cancers, compared to 9% or
18 out of 200, before the CDF reforms. Of these 24 drugs for rare cancers, 22 have
been recommended for routine commissioning and two for use within the CDF. This shows
that changes to the appraisal and funding of cancer drugs has led to an increase in
the number of treatments for rare cancers both assessed by NICE and funded by NHS
England in routine commissioning and via the CDF.</p><p> </p><p><strong> </strong></p>
|
|
